Today (April 29), A-Shares fluctuated upward, the Shanghai index rose more than 2% to recover the integer mark of 3000 points, the gem rose about 4%, and more than 200 shares in the two cities rose by the limit. On the disk, in terms of industries, electronic chemicals, education, mining, software development, cultural media, commercial department stores, auto parts, decoration and building materials, consumer electronics, games, precious metals and other industries increased higher. In terms of theme stocks, virtual digital human, hair medicine, hepatitis concept, data security, NFT concept, new retail, cloud games and other sectors performed prominently.
first quarter net profit increased by more than 130% CNOOC strong limit hit a new high since listing
CNOOC (600938) rose strongly on the 29th and closed the limit in the afternoon, setting a new high since its listing. In terms of news, the first quarter report of 2022 disclosed by the company yesterday showed that the company achieved an operating revenue of 90.898 billion yuan in the first quarter, a year-on-year increase of 73.52%; The net profit attributable to shareholders of listed companies was 34.301 billion yuan, a year-on-year increase of 131.67%; More than previously expected.
Previously, the company expected to achieve an operating revenue of about 69 billion yuan to 83 billion yuan in the first quarter, with a year-on-year increase of 32% to 58%; The net profit attributable to shareholders of the parent company was about 24 billion yuan to 28 billion yuan, a year-on-year increase of 62% to 89%.
Statistics show that CNOOC is the largest offshore crude oil and natural gas producer in China and one of the world's largest independent oil and gas exploration and production groups. By the end of 2020, the company had net proven reserves of about 5.37 billion barrels of oil equivalent, a record high; The service life of reserves has been maintained at more than 10 years in recent three years. From 2018 to 2020, the reserve substitution rate of the company was 126%, 144% and 136% respectively, and the reserve substitution rate remained high.
Cinda Securities said that whether it is traditional oil and gas resources or US shale oil, capital expenditure is the main reason for limiting crude oil production. Considering that the global capital expenditure on crude oil is insufficient for a long time, the elasticity of global crude oil supply will decline. In the transformation of old and new energy sources, the demand for crude oil is still growing, and the world will face the problem of crude oil shortage for many years. The international oil price will usher in an upward turning point in 2022. In the medium and long term, the oil price will remain high for a long time, and the energy resources are expected to be in an upward cycle in the next 3-5 years. We will continue to be firmly optimistic about this round of energy inflation, Continue to be firmly optimistic about the historic allocation opportunities of energy resources such as crude oil under the capacity cycle.
a shares and Hong Kong shares rose! Rising tide of Internet e-commerce concept Alibaba's share price exceeded 100 HK $
In the afternoon of April 29, the three major A-share indexes rose rapidly. The Internet e-commerce sector rose rapidly, and Aoki shares, Shanghai Kaytune Industrial Co.Ltd(301001) , Hangzhou Onechance Tech Corp(300792) , Nanji E-Commerce Co.Ltd(002127) , Shanghai Lily&Beauty Cosmetics Co.Ltd(605136) and other stocks rose by the limit.
In addition, the Hang Seng technology index of Hong Kong stocks rose strongly, the share price of Alibaba in Hong Kong stocks exceeded HK $100, and the gains of JD group and BiliBili were higher.
China Galaxy Securities Co.Ltd(601881) Securities said that although the external risk disturbance is still there, the focus should return to China's steady growth. Although the epidemic has disturbed China's economic development, the tone of China's steady growth will continue to work on the policy side, and investors' concerns will return to China's fundamentals. The dawn has come. We need to wait patiently for the policy to work, and investors' expectations and confidence are restored. We suggest that the allocation strategy is to find high-quality targets with both attack and defense under the two main lines of steady growth and high prosperity.
from next month, China's coal import tentative zero tax rate thermal power sector or concern
According to the official website of the Ministry of finance, in order to strengthen the guarantee of energy supply and promote high-quality development, the Tariff Commission of the State Council recently issued the announcement on adjusting coal import tariffs. The announcement said that from May 1, 2022 to March 31, 2023, the provisional import tax rate of zero will be implemented for all coal.
Tianfeng Securities Co.Ltd(601162) believes that with the coal price entering the downward channel, the cost pressure of thermal power generation is expected to be relieved, driving the improvement of profitability. At the same time, the market-oriented reform of electricity price continued to advance, the high price of electricity in many places rose, and some power generation costs were channeled downstream. Therefore, the performance of Q2 thermal power industry is expected to usher in marginal improvement. Under the background of the decline of thermal power investment, the coal price is expected to fall, which is expected to become a hedge in the thermal power industry.
Henan Yuneng Holdings Co.Ltd(001896) ( Henan Yuneng Holdings Co.Ltd(001896) ) company is deeply engaged in the energy industry, and the diversified development pattern has initially taken shape. It has become the only provincial capital holding comprehensive energy listed company in Henan province that integrates thermal power generation, new energy, pumped storage, coal trade logistics and comprehensive energy services.
Huadian Power International Corporation Limited(600027) ( Huadian Power International Corporation Limited(600027) ) company is one of the listed power generation companies with the largest installed capacity in China. Its power generation assets are distributed in 12 provinces, cities and autonomous regions across the country, with strong ability to resist system risks. In addition to coal-fired generator units, the installed types of power generation also include gas-fired power generation, hydropower generation and other types of units. The industrial chain is relatively perfect, and the coal industry, coal logistics and trade business are developed in the upstream.
Shanghai Electric Power Co.Ltd(600021) ( Shanghai Electric Power Co.Ltd(600021) ) power generation business is the core business of the company. By the end of 2021, the company's holding installed capacity was 190531 million KW, and clean energy accounted for 55.24% of the installed capacity, including 8.528 million kw of coal power, accounting for 44.76%, 2.8662 million kw of gas power, accounting for 15.04%, 3.7984 million kw of wind power, accounting for 19.94%, and 3.8605 million kw of photovoltaic power, accounting for 20.26%.
Guangdong gives subsidies for comprehensive use of new energy vehicles 8000 yuan / vehicles institutions are optimistic about the prospect of continuous demand release
The Guangdong Provincial Development and Reform Commission issued a notice on the subsidy activities for the purchase of new energy vehicles. Individual consumers who buy new new new energy vehicles within the range of models promoted by the "special action for replacing old vehicles with new ones in Guangdong Province" and complete the registration of motor vehicles in the province can apply for the subsidy for the comprehensive use of new energy vehicles.
This subsidy is not repeated with the subsidy of "Guangdong special action of replacing old cars with new ones". Provincial financial funds will give 8000 yuan / vehicle for comprehensive use of new energy vehicles to qualified consumers. The duration of the activity is from May 1, 2022 to June 30, 2022, and the date of the car purchase contract must be within this period.
Huajin Securities pointed out that the overall production and sales of new energy vehicles increased significantly from January to March 2022. Although in April, affected by the epidemic, some car companies stopped production or reduced production, which will inevitably affect the production and sales of new energy vehicles, we believe that vehicle electrification is still the general trend. The epidemic only delays its process to a certain extent, and we are still optimistic about the long-term development of the new energy vehicle industry chain. It's highly recommended to focus on: 's Contemporary Amperex Technology Co.Limited(300750) 35.
Everbright Securities Company Limited(601788) believes that it is optimistic about the prospect of continuous release of electric vehicle 2C demand. It is expected that vehicle enterprises are still expected to hedge policy fluctuations and cost rising pressure by retaining orders, time limited price protection, and comprehensive adjustment of price and equity, so as to drive the steady release of new orders; Among them, high-end pure electric vehicles, plug-in hybrid or market segments with strong certainty of sales growth, it is expected that production capacity, supply chain and logistics are still the leading factors affecting the climbing. According to the agency, the sales volume of Shanxi Guoxin Energy Corporation Limited(600617) passenger cars is expected to be 5-5.5 million in 2022e, and it is optimistic about car companies with strong model product cycle (chip supply mitigation, strong sales volume and profit elasticity), continuous increase of new energy penetration / clear and clear promotion path of intelligent electrification. In the passenger car sector, traditional car companies recommend Great Wall Motor Company Limited(601633) , Geely Automobile, suggest paying attention to Byd Company Limited(002594) , new forces recommend Tesla, and suggest paying attention to the ideal for a long time.
more than 80% of pharmaceutical enterprises increased their income last year outstanding performance in the anti epidemic sector
In 2021, when a series of medical insurance fee control policy reforms entered the deep-water area and many outbreaks occurred in many places, pharmaceutical and biological listed companies achieved gratifying results: more than 80% of the enterprises recorded a year-on-year increase in operating revenue last year, and more than 60% of the company's net profit achieved a year-on-year increase. From the perspective of subdivided fields, covid-19 testing, covid-19 vaccine and other anti epidemic related companies have achieved outstanding performance. On the basis of doubling or even several times of last year's annual net profit, many companies continued to achieve double high growth in the first quarter of this year.
According to statistics, as of press time, a total of 386 listed companies in Shenwan pharmaceutical and biological industry have issued 2021 annual reports, with an overall revenue of more than 2 trillion yuan. The median operating income and net profit were 1.5 billion yuan and 189 million yuan respectively. Among them, 244 companies had an operating revenue of more than 1 billion yuan in 2021, and 255 companies had a net profit of more than 100 million yuan, accounting for 63% and 66% respectively; There are only 39 loss making companies, 21 less than that in 2020; 20 companies turned losses into profits.
Shanghai Pharmaceuticals Holding Co.Ltd(601607) , Jointown Pharmaceutical Group Co.Ltd(600998) temporarily took the champion and runner up of operating revenue, with 215.8 billion yuan and 122.4 billion yuan respectively; The net profit of the top runner up is Chongqing Zhifei Biological Products Co.Ltd(300122) , Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) , which is 10.2 billion yuan and 8 billion yuan respectively. In terms of performance growth, the operating revenue of Shanghai Allist Pharmaceuticals Co.Ltd(688578) -u, Rongchang biology, Sinocelltech Group Limited(688520) -u, Cansino Biologics Inc(688185) u and the net profit of Beijing Hotgen Biotech Co.Ltd(688068) , Tianjin Lisheng Pharmaceutical Co.Ltd(002393) , Harbin Medisan Pharmaceutical Co.Ltd(002900) all increased by more than 100 times last year.
In addition, in the first quarter of this year, the achievements of pharmaceutical and biological enterprises were still bright. 148 companies achieved double growth in operating revenue and net profit, accounting for 54% of the total number of enterprises that have released the first quarterly report. In addition to the anti epidemic sector, enterprises of traditional Chinese medicine, API and chemical agents generally achieved performance growth.
From the perspective of subdivided industries, the performance of Companies in the track of medical devices and chemical agents is outstanding, especially covid-19 vaccine and covid-19 test related to anti epidemic. The average operating revenue of 35 covid-19 testing related enterprises increased by 67% last year, and the average net profit increased by 112%.
The net profit of Cansino Biologics Inc(688185) , Zhejiang Orient Gene Biotech Co.Ltd(688298) , Daan Gene Co.Ltd(002030) and other pharmaceutical enterprises hit a record high last year. Among them, Cansino Biologics Inc(688185) 2021 achieved a net profit attributable to the parent company of 1.914 billion yuan, making a profit for the first time. The securities abbreviation was changed from " Cansino Biologics Inc(688185) -u" to " Cansino Biologics Inc(688185) ", becoming the first pharmaceutical enterprise to successfully "pick u" on the science and innovation board.
In the first quarter of this year, enterprises in covid-19 testing sector continued to maintain a high growth trend Zhejiang Orient Gene Biotech Co.Ltd(688298) in the first quarter of this year, the annual net profit increased by 74% on the basis of 193% year-on-year Hangzhou Biotest Biotech Co.Ltd(688767) net profit increased by 111% in the first quarter of this year, up from 91% last year. In addition, the net profit growth of Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) , Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) , Guangdong Hybribio Biotech Co.Ltd(300639) , Xilong Scientific Co.Ltd(002584) and other companies exceeded 100% in the whole year of last year and the first quarter of this year. Andon Health Co.Ltd(002432) , which has successively won a large order of covid-19 antigen detection reagents in the United States, is expected to have a net profit of more than 14 billion yuan in the first quarter of this year, with a year-on-year increase of more than 367 times.
